Accurate predictions of PK would enable better decisions regarding the selection of compounds for in vivo studies, reducing the number of experiments required and the associated cost. But, this is particularly challenging because in vivo PK is influenced by many biological mechanisms.

In this webinar, Tom Whitehead of Intellegens' Head of Machine Learning, described the successful application of the Alchemite™ method for deep learning imputation to the prediction of PK parameters, based on compound structure and sparse in vitro data.

This project was undertaken in collaboration with AstraZeneca, and we were delighted to be joined by Nigel Greene, AZ's Director of Data Science & AI, who discussed their research in this area.